Get started

Gartley

## CreditAccess Grameen (CREDITACC) Share Price Analysis- As of May 2, 2025, CreditAccess Grameen (CREDITACC) traded around ₹1,121–₹1,145, which is approximately 52% above its 52-week low of ₹750.20 (set in January 2025), but below its 52-week high of ₹1,551.95 (set in June 2024) . - The stock has shown volatility over the past year, with a notable decline from its peak, reflecting both sector trends and company-specific events . **Valuation and Financial Metrics** - **P/E Ratio (TTM):** 20.3–21.2, indicating moderate valuation relative to earnings . - **Book Value:** ₹438 per share, with the stock trading at about 2.6 times book value, which is considered on the higher side for the sector . - **Dividend Yield:** Around 0.86–0.89%, with recent dividend payouts . - **Return on Equity (ROE):** 24.8% (latest year), reflecting strong profitability . - **Return on Capital Employed (ROCE):** 14.8% . **Growth and Profitability** - The company has delivered robust profit growth (35% CAGR over the last 5 years) and strong median sales growth (31.6% over 10 years) - However, profit growth has turned negative in the trailing twelve months (-35%), primarily due to higher provisioning and write-offs in recent quarters - The company reported a loss of ₹99.5 crore in Q3 FY25, mainly due to early risk recognition, conservative provisioning, and accelerated write-offs, but management expects this to safeguard future profitability as growth normalizes **Operational Highlights** - **Assets Under Management (AUM):** Grew by 6.1% YoY to ₹24,810 crore in Q3 FY25 - **Borrower Base:** Increased by 2.4% YoY to 48.05 lakh customers - **Branch Network:** Expanded by 8.7% YoY to 2,059 branches - **Collection Efficiency:** Remained robust at 93.3% (excluding arrears) and 94.1% (including arrears), with improving trends - **Asset Quality:** PAR 90+ at 2.64%, NNPA at 1.28%, indicating some stress but manageable levels - **Capital Adequacy:** CRAR at 25.9%, reflecting a strong capital position **Strengths and Risks** **Strengths:** - Consistent long-term growth in profits and sales - Strong capital position and liquidity buffer - High collection efficiency and expanding branch network **Risks/Concerns:** - Recent decline in promoter holding (-7.42% over three years) - Low interest coverage ratio, suggesting higher financial risk - Elevated provisioning and write-offs impacting near-term profitability - Stock is trading at a premium to book value, which may limit upside if growth slows **Relative Performance** - Over the past year, the stock is down 24%, underperforming the broader market, but over five years, it has delivered a 154% return, broadly in line with sector peers - In the short term (last three months), the stock has rebounded by about 13% from its lows ## Summary CreditAccess Grameen remains a leading NBFC-MFI with a strong track record of growth and profitability. While recent quarters have seen a dip in profits due to prudent risk management and provisioning, the company’s fundamentals-such as robust capital adequacy, liquidity, and operational scale-remain intact. The stock is moderately valued but carries risks related to asset quality and sector volatility. Investors should watch for normalization of growth and profitability in upcoming quarters, as indicated by management
NSE:CREDITACCLong
by KarniKripaa
ERIS Lifesciences Share Price AnalysisEris Lifesciences is currently trading in the range of ₹1,371 to ₹1,474, with the latest reported price at ₹1,474.20 as of April 23, 2025. The stock has shown strong performance over the past year, delivering a return of approximately 57%. Over the last three months, the stock is up about 9%, though it has seen a slight dip of 0.57% in the past month. **Valuation and Fundamentals** Eris Lifesciences trades at a price-to-earnings (P/E) ratio of 57.13, which is high for the sector, and a price-to-book (P/B) ratio of 4.53. The company’s earnings per share (EPS) stands at 29.19, and its return on equity (ROE) is 12.63%, indicating moderate profitability. The market capitalization is approximately ₹18,831 crore . The dividend yield is negligible, suggesting the company focuses more on growth than on returning cash to shareholders. **Analyst Sentiment and Targets** Analyst sentiment is strongly positive, with nearly 89% recommending a buy and the remainder suggesting hold; there are no sell recommendations. The average long-term price target from analysts is ₹1,512.56, indicating modest upside from current levels. **Technical and Trading Overview** The stock has recently traded near its upper circuit of ₹1,659.60, with a lower circuit at ₹1,106.40, reflecting a relatively wide trading band and potential for volatility. Recent trading volumes have been healthy, supporting the current price momentum. **Summary** Eris Lifesciences has delivered strong returns over the past year and is viewed positively by analysts. However, its high P/E ratio suggests the stock is priced for continued growth, and the lack of dividend yield may not appeal to income-focused investors. The technical outlook is stable, with the stock trading near its highs and supported by robust trading activity.
NSE:ERISLong
by KarniKripaa
NTPC price analysisNTPC is currently trading around ₹360, having shown a modest gain of about 4% over the past year. The stock reached its all-time high of ₹448.45 in September 2024 and has since pulled back, with recent price action reflecting some consolidation after a strong multi-year rally . Over the last month, NTPC has delivered a positive return of approximately 2.5%, indicating some short-term strength despite a slight decline of nearly 1.8% in the past week. Fundamentally, NTPC remains a large-cap, stable utility with a market capitalization near ₹3.5 lakh crore and a price-to-earnings (PE) ratio of about 15.9, which is below the industry average, suggesting reasonable valuation. The company boasts a healthy dividend yield of 2.5%, and its return on equity (ROE) stands at 13.1%. Promoter holding remains steady at 51.1%, and the company continues to report strong profits, with net profit for the latest fiscal year exceeding ₹20,000 crore. Analyst sentiment is generally positive, with some brokerages forecasting up to 35% further upside from current levels and price targets ranging between ₹305 and ₹500 for 2025. Technical indicators and historical trends show NTPC often delivers positive returns in April, with an average gain of about 3% for the month In summary, NTPC is viewed as a fundamentally sound, dividend-paying stock with moderate growth prospects and reasonable valuation. While the stock is off its recent highs, the outlook remains constructive, supported by positive earnings, stable fundamentals, and favorable long-term forecasts from analysts
NSE:NTPCLong
by KarniKripaa
1
Fortis Healthcare’s share price analysisFortis Healthcare’s share price is currently around ₹667, reflecting strong momentum and significant outperformance over the past year, with a return of about 49%. The stock recently touched a 52-week high of ₹744.5 and a low of ₹406, indicating a broad trading range and robust investor interest Analyst sentiment remains bullish, with most forecasts targeting a price range of ₹736 to ₹850 over the next 12 months, suggesting a potential upside of around 10–20% from current levels . Some projections are even more optimistic, with year-end 2025 targets as high as ₹933 if market conditions remain favorable . Technical indicators currently point to a bullish trend, supporting the positive outlook . Fundamentally, Fortis Healthcare has reported strong financial results, including an 84% year-on-year jump in net profit for Q3 FY2024-25 and a 40% quarterly profit increase, underscoring operational momentum . The company trades at a price-to-earnings (PE) ratio of about 65, which is above the sector average, indicating that the stock is priced at a premium due to its growth prospects . The price-to-book (PB) ratio is 3.49, and the dividend yield is modest at 0.24% . In summary, Fortis Healthcare is in a bullish phase, supported by strong earnings growth and positive analyst outlooks. While the stock is trading at a premium valuation, its growth trajectory and sector leadership continue to attract investor interest, with further upside likely if current trends persist
NSE:FORTISLong
by KarniKripaa
## TORNTPHARM Price AnalysisTorrent Pharmaceuticals (TORNTPHARM) is currently trading near ₹3,254, maintaining a strong uptrend over the past several years. The stock has delivered a return of approximately 165% from July 2020 to November 2024, including a stock split, highlighting its consistent long-term growth. **Valuation and Fair Value** TORNTPHARM is trading well above its estimated intrinsic value. Independent valuations suggest a fair value in the range of ₹1,560 to ₹1,940 per share, meaning the current market price is overvalued by about 40%. The price-to-earnings (PE) ratio stands at approximately 59–66, which is significantly higher than the sector average of around 49, indicating a premium valuation. The price-to-book (PB) ratio is also elevated at 16, compared to the sector average of 6.29. **Recent Performance** The stock has shown positive momentum in the short term, with returns of 3.5% over the past week and 5.7% over the past month. Over the last year, TORNTPHARM has gained nearly 28%, and over three years, the return is more than 128%. Despite some volatility, the stock has outperformed many of its peers and the broader market. **Fundamental Trends** Torrent Pharma’s India business, which constitutes the bulk of its revenue, grew by 12% in Q3 FY25, driven by strong performance in branded generics. However, the company faces challenges in international markets, particularly the US, due to regulatory headwinds and pricing pressures. Revenue growth over the past five years has averaged 7% annually, slightly below the industry average, but net income growth has been robust at over 30% per year, outpacing peers. **Analyst Outlook** Analysts have a moderately positive outlook, with a one-year price target averaging around ₹3,600, and a range between ₹2,959 and ₹4,200 . About 68% of analysts currently rate the stock as a buy. **Dividend and Market Cap** The dividend yield is 0.86%, which is above the sector average, and the company’s market capitalization is approximately ₹1.1 lakh crore, placing it among the larger players in the Indian pharmaceutical sector. **Summary** TORNTPHARM has demonstrated strong long-term price appreciation and profitability, but it is currently trading at a significant premium to its estimated intrinsic value. Short-term technicals are mixed, with some bullish undertones, but caution is warranted due to high valuation multiples. The company’s growth is primarily driven by its domestic business, while international operations face ongoing challenges. Analyst sentiment remains positive, but the upside may be limited unless earnings growth accelerates or valuation multiples contract.
NSE:TORNTPHARMLong
by KarniKripaa
Som Distilleries & Breweries Ltd (SDBL) Price Analysis - **Current Price:** ₹156.00 (all-time high as of April 22, 2025) - **Day’s Range:** ₹127.66 – ₹143.40 - **Previous Close:** ₹128.38 - **Volume:** 13.36 million (well above 20-day average of 1.34 million) - **52-Week Range:** ₹95.61 – ₹148.90 (new all-time high today) - **VWAP:** ₹137.86 - **Market Cap:** ₹2,931 crore ### **Trend & Momentum** - SDBL has surged sharply, breaking out to a new all-time high with exceptionally high volume, indicating strong bullish momentum - The stock has rallied over 20% in a single session, moving far above recent resistance levels and its VWAP - Technical patterns suggest a bullish formation with potential for further upside, possibly another 10% move, according to chartists ### **Support & Resistance** - **Immediate Support:** ₹143.40 (today’s high), then ₹127.66 (today’s low), and ₹128.38 (previous close) - **Resistance:** With a new all-time high at ₹156.00, the stock is in price discovery; next resistance will form as the stock trades higher ### **Valuation** - **TTM PE:** 30.48 (sector PE: 88.54) - **P/B:** 4.75 - **EPS (TTM):** ₹4.67 (+5.28% YoY) - **Book Value per Share:** ₹30.02 ### **Outlook** - **Short-Term:** The breakout and volume spike suggest continued bullishness. However, after such a sharp rally, some profit booking or volatility is possible. - **Medium-Term:** Sustained trade above ₹143–₹148 keeps the trend positive. Watch for consolidation near new highs before the next leg up. - **Downside Risk:** If the stock falls below ₹143, it may retest support around ₹128–₹130
NSE:SDBLLong
by KarniKripaa
Piramal Pharma (PPLPHARMA) Stock Price Analysis**Piramal Pharma (PPLPHARMA) Indian Stock Price Analysis – April 22, 2025** - **Current Price:** ₹220.70 (as of April 21, 2025) - **Short-Term Trend:** Sideways to weak. The stock has been volatile, trading mostly between ₹217 and ₹225 in recent sessions - **Recent Performance:** - 1 week: +1.86% - 1 month: +6.36% - 3 months: –4.46% - 1 year: +55.38% - **Moving Averages:** The stock is above its 50-day moving average but below the 5-day, 20-day, 100-day, and 200-day moving averages, indicating mixed momentum and some weakness in the short term - **Support:** ₹217 - **Resistance:** ₹225–₹231 - **Volatility:** High; the stock is 3.27x as volatile as the Nifty - **Sector Comparison:** Underperforming its sector in the short term, but strong annual gains - **Analyst View:** Mixed; some analysts suggest buying for the long term, but caution is warranted in the short term due to recent weakness **Summary:** PPLPHARMA has shown strong gains over the past year but is currently consolidating with a slight bearish bias. The price is range-bound, with support at ₹217 and resistance around ₹225–₹231. Watch for a breakout above resistance for renewed bullish momentum, or a drop below support for further downside risk
NSE:PPLPHARMALong
by KarniKripaa
Nalwa Sons Investment Ltd. (NSIL) Price Analysis### Nalwa Sons Investment Ltd. (NSIL) Price Analysis as of April 1, 2025: #### **Current Price and Recent Trends** - **Current Price (April 1, 2025):** ₹6,594.30 (Range: ₹6,268.53 - ₹6,895.56) - **Previous Close (March 31, 2025):** ₹6,449.86 - **52-Week Range:** ₹2,245.15 - ₹9,974.00 - **All-Time High:** ₹9,974.00 #### **Key Metrics** - **Market Cap:** ₹3,113 crore . - **P/E Ratio (TTM):** 42.08 (High compared to sector average of 31.94) - **Book Value Per Share:** ₹15,518.22 . - **Dividend Yield:** 0% #### **Technical Indicators** - **Technical Strength:** Strong bullish momentum observed recently - **RSI and EMA Trends:** Indicate positive momentum with potential for short-term gains - **Volume Trends:** Average 20-day volume at 12,620 shares with a delivery percentage of 65.43% #### **Forecast** - **Short-Term Forecast (April 2, 2025):** Projected price range of ₹6,320.26 - ₹6,934.05 with an expected close around ₹6,613.46 - **Long-Term Outlook:** Potential growth of approximately 6.81% in one year with a target price of ₹6,570.93 #### **Strengths and Weaknesses** **Strengths:** - Excellent stability and strong technical indicators. - Low Price-to-Book ratio of 0.39 suggests undervaluation relative to book value **Weaknesses:** - High P/E ratio indicates expensive valuations. - Low profitability metrics such as ROA (0.45%) and ROE (0.53%)
NSE:NSILLong
by KarniKripaa
Kotak Mahindra BankKotak Mahindra Bank - Technical Analysis & Key Insights 📌 Chart Patterns Identified: 🔻 Cypher Pattern (Bearish Reversal Zone) – If the price faces rejection, it may decline towards the 🟥 Handle Retest Range. 🔼 Cup & Handle Pattern (Bullish Breakout Signal) – If the price sustains above 🔵 ₹1,938.85 (Breaking Range), an upward breakout is expected. 📊 Key Levels & Targets: 🔵 Breaking Range: ₹1,938.85 (Confirmation Level for trend direction). 🟥 Handle Retest Range: ₹1,805 - ₹1,858 (Potential pullback zone before resuming trend). 🟢 Bullish Target Levels: 🎯 Target 1: ₹2,071.45 🎯 Target 2: ₹2,286.35 🔻 Bearish Target: ₹1,591.30 (If a downward breakdown occurs). ⚖️ Risk-Reward Ratio & Market Sentiment: 📈 Upside Potential: +22.84% (Bullish breakout possibility). 📉 Downside Risk: -11.67% (If bearish reversal happens). 📊 Market Sentiment: Neutral to Bullish (but needs confirmation). 📌 Trading Strategy: ✅ Bullish Entry: If price stays above ₹1,938.85 with strong volume confirmation. or Handle retest range 1858 ❌ Bearish Entry: If price breaks below ₹1,858 and fails to reclaim resistance. ⚠️ Stop-loss & Risk Management: Set SL below the retest range to minimize potential losses. 📌 Additional Factors to Consider: 📢 Volume Confirmation: A strong breakout should be backed by increased trading volume. 📰 Fundamental News: Earnings reports, RBI policies, and global market trends could impact stock movements. 📊 Support & Resistance: Price action near key levels should be closely monitored for validation. ⚠️ Disclaimer: This analysis is for educational purposes only and not financial advice. 📉📈 Stock market investments are subject to risk; always do your own research before making trading decisions. 🚀
NSE:KOTAKBANKLong
by BUY_TODAY_Tamil
BANK NIFTY TODAYS LOW IS AN IMPORTANT SUPPORT LEVELIf you see todays low this is an important level if you believe in HISTORY repeats you can see clearly white line upper and lower band bank nifty touched lower one and bouncing back axcept this many of the times it is taken support at this level shown by green arrow mark other than this my down side gann fan 1/4 line crosses previous gann fan line2/1 which is in orange and blue colored. if you buy or sell thisn will be your decision becaus it is not my buy/sell call.
NSE:BANKNIFTYLong
by OVIMONT
GARTLEY Harmonic Pattern: How does it work?!GARTLEY Harmonic Pattern: How does it work?! The "Gartley", as its name suggests, was introduced by Henry Mackinley Gartley. All other harmonic patterns are modifications of the Gartley. Its construction consists of 5 waves: XA: This could be any violent movement on the chart and there are no specific requirements for this movement in order to be a Gartley start AB: This is opposite to the XA movement and it should be about 61.8% of the XA movement. BC: This price movement should be opposite to the AB movement and it should be 38.2% or 88.6% of the AB movement. CD: The last price movement is opposite to BC and it should be 127.2% (extension) of CD if BC is 38.2% of BC. If BC is 88.6% of BC, then CD should be 161.8% (extension) of BC. AD: The overall price movement between A and D should be 78.6% of XA How to use it Point D is where you come in, man! It's your entry signal. -If it's an M pattern, you buy. -If it's a W, you sell2. Where to put your STOP LOSS?? -Below or "X" if you are a BUYER. -Above "X" if you are a SELLER. These percentages are based on the famous Fibonacci ratios, as mysterious as the pyramids of Egypt! Ultimately, the Gartley pattern is like a good Cuban cigar: it requires patience and experience to be appreciated at its true value. But once you master it, it can become a powerful tool in your trading arsenal, as effective as a punch from Rocky Balboa!
BINANCE:BTCUSDEducation
by Le-Loup-de-Zurich